GlassScriptPhysician profile
Julie Dana Asch
NPI 1083740070
$61,933.03
in general payments reported to CMS, 2019-2025
10 companies · $51K in 2025
The $51K reported for 2025 was more than what 97% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.99 · 2020: $54.69 · 2021: $150 · 2022: $113 · 2023: $1,370 · 2024: $8,903 · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Travel and Lodging: $7,114 · Consulting Fee: $1,933 · Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,840.00 |
| Travel and Lodging | $7,114.40 |
| Consulting Fee | $1,932.52 |
| Food and Beverage | $1,708.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $57,819.00 | 2024-2025 | |
| Amgen INC. | $2,069.30 | 2023-2025 | Blincyto, Blincyto |
| Adaptive Biotechnologies Corporation | $1,419.10 | 2024 | Clonoseq |
| Incyte Corporation | $172.58 | 2022-2025 | Niktimvo |
| Alexion Pharmaceuticals, INC. | $163.89 | 2021-2022 | |
| Kite Pharma, INC. | $155.52 | 2019-2024 | Yescarta |
| Novartis Pharmaceuticals Corporation | $78.95 | 2023 | |
| Rigel Pharmaceuticals, INC. | $54.69 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Asch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.